INZ-701 is a fusion protein commercialized by Inozyme Pharma, with a leading Phase III program in Arterial Calcification. According to Globaldata, it is involved in 9 clinical trials, of which 7 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of INZ-701’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for INZ-701 is expected to reach an annual total of $94 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

INZ-701 Overview

INZ-701 is under development for the treatment of rare genetic diseases of ENPP1 deficiency (generalized arterial calcification infancy (GACI) and autosomal recessive hypophosphatemic rickets type II (ARHR2), rare genetic diseases of ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), calciphylaxis, end-stage kidney disease (ESKD) and diseases of neointimal proliferation. It is administered through subcutaneous route. 

Inozyme Pharma Overview

Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company that develops novel therapeutics for the treatment of rare genetic diseases of ENPP1, ABCC6 deficiencies and impacting the vasculature, soft tissue and skeleton. It is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$68.7 million in FY2022, compared to an operating loss of US$56.7 million in FY2021. The net loss of the company was US$67.1 million in FY2022, compared to a net loss of US$56.6 million in FY2021.

For a complete picture of INZ-701’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.